The changes of these serum adipokines and factors triggered by the FGFR4 deficiency are generally consistent with the observed net tumor suppressive effect, and thus support our notion that the effect of FGFR4 deficiency on delaying breast cancer progression lies in the alteration of metabolic pathways governed by eFGF signaling and other systemic factors. This evidence concerns the gene FGFR4 and breast cancer.